CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Lamivudine/ Placebo 100mg dailydrug
Likely dose
Lamivudine/ Placebo 100mg dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00338780
NCT00338780Phase 4Completed
CompareCT.gov

A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

Chinese University of Hong Kong·interventional·Posted Jun 20, 2006·Updated Oct 30, 2006

In Brief

A Phase 4 clinical trial evaluating Lamivudine/ Placebo 100mg daily for Chronic Hepatitis B. Completed, across 1 site.

Detailed Summary

The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesChina
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2006
Enrollment StartNov 1, 2000
Study CompletionJan 1, 2005
TodayJul 2, 2026
Posted 20.0 years ago

Interventions

Lamivudine/ Placebo 100mg dailydrug